Pregnancy (Hoboken, N.J.)最新文献

{"title":"Interventions following routine hemoglobin assessment after vaginal delivery.","authors":"Sarah Fujiwara, Andrea Siu, Kelly Yamasato","doi":"10.1002/pmf2.70438","DOIUrl":"10.1002/pmf2.70438","url":null,"abstract":"<p><strong>Objective: </strong>To assess the utility of routine postpartum hemoglobin (Hgb) testing after vaginal delivery with normal blood loss by evaluating the frequency of blood transfusion and intravenous (IV) iron administration.</p><p><strong>Methods: </strong>This retrospective cohort study included vaginal deliveries with blood loss <500 mL at a tertiary hospital between January 2020 and May 2025. Patients with missing blood loss data, preeclampsia/eclampsia, or a hemorrhage diagnosis were excluded. Predelivery and postpartum Hgb values, as well as blood transfusion and IV iron administration, were collected. The primary outcomes were postpartum blood transfusion and IV iron administration. Univariate logistic regression was used to identify variables associated with blood transfusion and IV iron administration. Multivariable logistic regression was then performed to evaluate independent predictors of each outcome. Manual chart review was performed for those who received a blood transfusion or IV iron to identify signs of anemia and relevant comorbidities.</p><p><strong>Results: </strong>Of 21,719 vaginal deliveries, 11,180 were included. Of these, 10,075 (90.1%) underwent postpartum Hgb testing with a mean Hgb decrease of 1.3 g/dL (SD, 0.9) pre- to postdelivery. Among the 11,180 deliveries, 19 (0.2%) received blood transfusion, and 82 (0.7%) received IV iron. Higher predelivery Hgb was associated with lower odds of blood transfusion (odds ratio [OR], 0.27; 95% confidence interval [CI], 0.19-0.38) and IV iron administration (OR, 0.25; 95% CI, 0.20-0.30). Among the 10,954 deliveries with predelivery Hgb ≥9 g/dL, six (0.05%) received blood transfusion. Of these six patients, five had anemia symptoms (<i>n</i> = 1) or comorbidities, including sepsis (<i>n</i> = 2) and vaginal hematoma (<i>n</i> = 2). Thirty-nine patients with a predelivery Hgb ≥9 g/dL received IV iron, of whom 13 (33.3%) had anemia symptoms and/or comorbidities. Among patients with predelivery Hgb ≥9 g/dL, normal blood loss, and no symptoms or comorbidities, the probability of receiving a blood transfusion or IV iron was 0.23% (one blood transfusion and 26 IV iron infusions). Applying a predelivery Hgb threshold of ≥9 g/dL to guide selective postpartum testing would have avoided 98% of routine assessments while maintaining 99.8% sensitivity for identifying patients who received a blood transfusion or IV iron.</p><p><strong>Conclusion: </strong>In this large cohort of vaginal deliveries with normal blood loss, blood transfusion and IV iron administration were rare. Selective postpartum Hgb testing based on predelivery Hgb and symptoms or comorbidities can be considered.</p>","PeriodicalId":520540,"journal":{"name":"Pregnancy (Hoboken, N.J.)","volume":"2 5","pages":"e70438"},"PeriodicalIF":0.0,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13555611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148922564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Placental pathology in fetuses with and without congenital heart defects.","authors":"Tucker E Doiron, Sherri Besmer, Jessenia Guerrero, Joanne Salas, Lauren Fox, Emily Zantow, Niraj R Chavan","doi":"10.1002/pmf2.70439","DOIUrl":"10.1002/pmf2.70439","url":null,"abstract":"<p><strong>Introduction: </strong>Placental histopathologic evaluation of pregnancies affected by congenital heart defects (CHDs) can provide insight into the mechanism connecting placental and fetal vascular systems. The objective of this study was to evaluate the prevalence of maternal vascular malperfusion (MVM) and fetal vascular malperfusion (FVM) lesions of the placenta in pregnancies with and without fetal CHD on blinded pathologic examination.</p><p><strong>Methods: </strong>This is a case-control study of pregnancies complicated by CHD at our institution from January 1, 2011 to June 25, 2021. Controls were matched to cases in a 2:1 ratio based on maternal age and gestational age at delivery. Placental and umbilical cord pathology slides were deidentified prior to standardized pathologic examination. There were two primary composite outcomes: MVM and FVM. The MVM composite included infarction and villous and vascular lesions. The FVM composite included thrombosis, villous lesions, and cord abnormalities. Primary composite outcomes were evaluated based on the presence or absence of a fetal CHD using <i>t</i>-tests and chi-squared or Fisher's exact tests, and a multivariable, conditional logistic regression model controlling for relevant confounding variables. Subgroup analysis was performed for those with and without maternal cardiovascular risk factors in the CHD group and for primary outcomes by cardiac lesion type.</p><p><strong>Results: </strong>A total of 351 patients were included: 117 cases and 234 controls. The CHD cohort had higher rates of neonatal intensive care unit (NICU) admission (91.5% vs. 22.2%, <i>p</i> < 0.001), neonatal death (12.8% vs. 0%, <i>p</i> < 0.001), and placental chorangiosis (12.0% vs. 4.7%, <i>p</i> = 0.01). Pregnancies with CHD were also more likely to have the FVM composite outcome (odds ratio [OR], 1.88; confidence interval [CI], 1.20-2.97), specifically villous lesions (26.5% vs. 10.7%, <i>p</i> = 0.0001), avascular villi (22.2% vs. 9.8%, <i>p</i> = 0.002), and a two-vessel umbilical cord (6.8% vs. 0.9%, <i>p</i> = 0.003). The MVM composite did not differ between groups. In the multivariable regression, the CHD group had higher odds of experiencing the FVM composite (OR, 2.01; CI, 1.14-3.56). Within the CHD cohort, those with hypertensive disorders of pregnancy were associated with the MVM composite outcome (53.9% vs. 36.2%, <i>p</i> = 0.05).</p><p><strong>Conclusions: </strong>On blinded pathology review, those with fetal CHD were more likely to have FVM lesions. MVM lesions did not show an association with CHD in our cohort.</p>","PeriodicalId":520540,"journal":{"name":"Pregnancy (Hoboken, N.J.)","volume":"2 5","pages":"e70439"},"PeriodicalIF":0.0,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13555614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148922521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Neonatal impact of maternal biomarker screening for risk of preterm birth with targeted interventions (PRIME): A multicenter, randomized, controlled trial\".","authors":"","doi":"10.1002/pmf2.70437","DOIUrl":"https://doi.org/10.1002/pmf2.70437","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1002/pmf2.70202.].</p>","PeriodicalId":520540,"journal":{"name":"Pregnancy (Hoboken, N.J.)","volume":"2 5","pages":"e70437"},"PeriodicalIF":0.0,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148908578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Congenital heart disease in pregnancy and severe maternal morbidity: a distributed data network study.","authors":"Elizabeth B Sherwin, Benjamin Martin, Xiao Xu, Anna Booman, Alyssa Howren, Kimberlee McKay, Sadaf Kazi, Sean O'Reilly, Katie S Kolla, Khyzer Aziz, Katherine Bianco, Stephanie A Leonard","doi":"10.1002/pmf2.70370","DOIUrl":"10.1002/pmf2.70370","url":null,"abstract":"<p><strong>Introduction: </strong>Pregnant people with congenital heart disease (CHD) are a growing patient population in obstetrics, yet evidence on the risk for severe maternal morbidity (SMM) has largely been limited to studies that lack specificity for CHD. We conducted this study to demonstrate the utility of distributed data networks for obstetric research and to characterize pregnant patients with CHD and their risk of SMM.</p><p><strong>Methods: </strong>The study included female patients aged 12-55 years who delivered between 2015 and 2026 at three U.S. academic healthcare organizations. We used a distributed data network study design by developing analytical code, executing the code locally at each organization using its electronic health record (EHR) data in a common data model (CDM), then aggregating the results. This analytical approach is rigorous, reproducible, and protects patient confidentiality by not sharing patient-level data. The Observational Medical Outcomes Partnership (OMOP) CDM was used by each organization, and we used OMOP standard concepts to identify CHD and SMM. We categorized outcomes as SMM, non-transfusion SMM, and cardiac SMM based on the CDC SMM index. We analyzed the incidence of the outcomes and estimated risk ratios (RRs) and Wald 95% confidence intervals (CIs) using contingency tables.</p><p><strong>Results: </strong>The prevalence of CHD in pregnancy was 2.20% among 166,033 deliveries across three healthcare organizations. 19.30% of people with CHD had an acquired heart condition, compared to 2.14% of people without CHD. SMM occurred in 9.43% of deliveries to people with CHD compared to 4.53% among people without CHD (RR: 2.08; 95% CI: 1.88, 2.31), and non-transfusion SMM occurred in 6.72% vs 2.55% of deliveries (RR: 2.63; 95% CI: 2.33, 2.98), respectively. Cardiac SMM represented 51.84% of non-transfusion SMM among people with CHD compared to 16.18% among people without CHD.</p><p><strong>Conclusions: </strong>Our distributed data network study using EHR data from three geographically diverse U.S. healthcare organizations found that 1 in 15 people with CHD had non-transfusion SMM compared with 1 in 39 people without CHD. This study demonstrates the feasibility and utility of distributed data networks for obstetric research and provides novel evidence on maternal outcomes for pregnant patients with CHD.</p>","PeriodicalId":520540,"journal":{"name":"Pregnancy (Hoboken, N.J.)","volume":"2 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13449514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148698747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy and glycemic outcomes with hybrid closed-loop insulin delivery versus sensor-augmented pump therapy among women with type 1 diabetes.","authors":"Annabeth Brewton, Radhika Pandit, Jiqiang Wu, Natasha Santhanam, Ellena Privitera, Shaylyn Vickers, Steven Gabbe, William A Grobman, Mark B Landon, Christine P Field, Elizabeth O Buschur, Kartik K Venkatesh","doi":"10.1002/pmf2.70392","DOIUrl":"10.1002/pmf2.70392","url":null,"abstract":"<p><strong>Objective: </strong>Pregnant women with type 1 diabetes (T1D) increasingly utilize hybrid closed-loop (HCL) pumps, but <i>pregnancy-specific</i> algorithms in many countries including the United States are not available. We compared pregnancy and glycemic outcomes between those intending to use off-label automated HCL versus manual sensor-augmented pump therapy (SAPT).</p><p><strong>Methods: </strong>We conducted a single-center retrospective study from 2022 to 2025. The exposure was intent to use HCL using non-pregnancy algorithms versus SAPT (reference) at the start of pregnancy. Outcomes included pregnancy outcomes (cesarean delivery, preeclampsia, preterm birth, small- and large-for-gestational-age, neonatal intensive care unit admission, neonatal hypoglycemia, neonatal hyperbilirubinemia, and respiratory distress syndrome) and glycemic measures the week before delivery (hemoglobin A1c and continuous glucose monitor metrics including time in range within a pregnancy-specific range [63-140 mg/dL], time above and below range, standard deviation, and mean glucose). An Inverse-Probability-of-Treatment Weighting analytic approach was used.</p><p><strong>Results: </strong>Among 154 women with T1D, 68.2% intended to use HCL and 31.8% SAPT when initiating prenatal care (median gestational age of 8.0 weeks [interquartile range {IQR}, 7.3, 9.3]). In adjusted analyses, women using HCL had neonates with a higher birthweight (3640 vs. 3430 g; adj. beta, 271.98; 95% CI, 0.31, 543.65) and mean sensor glucose the week prior to delivery (150.0 vs. 145.0 mg/dL; adj. beta, 13.36; 95% CI, 0.79, 25.93) and lower time below range compared with those using SAPT (2.0 vs. 4.0%; adj. beta, -3.73; 95% CI, -6.52, -0.93). Other pregnancy and glycemic outcomes did not differ between groups.</p><p><strong>Conclusion: </strong>Among a US cohort with T1D enrolled in a prenatal and diabetes care program, pregnancy and glycemic outcomes were similar between those using off-label HCL versus SAPT. Evaluating how HCL with pregnancy-specific algorithms can be used to promote maternal and child health could be most helpful for pregnant women with T1D and should be a research priority.</p>","PeriodicalId":520540,"journal":{"name":"Pregnancy (Hoboken, N.J.)","volume":"2 5","pages":"e70392"},"PeriodicalIF":0.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13527856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148868812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obstetricians' and midwives' attitudes and perceived barriers to the implementation of immediate postpartum diabetes testing.","authors":"Verónica Maria Pimentel, Charissa Joy Okang, Nicole Barreto, Dorothy Wakefield, Rebecca Crowell","doi":"10.1002/pmf2.70378","DOIUrl":"10.1002/pmf2.70378","url":null,"abstract":"<p><strong>Background: </strong>Gestational diabetes mellitus (GDM) is increasingly prevalent and is a major risk factor for type 2 diabetes mellitus (DM2). Completion of the conventional 4-12-week postpartum diabetes testing remains low. In May 2024, the American College of Obstetricians and Gynecologists (ACOG) endorsed immediate postpartum diabetes (IPD) testing as an alternative, citing comparable diagnostic performance and higher completion rates. Little is known about the attitudes and practices of obstetricians and midwives regarding IPD testing. The objectives of our study were to assess obstetricians' and midwives' familiarity with IPD testing, willingness to adopt this testing strategy, and the barriers and facilitators to its implementation.</p><p><strong>Methods: </strong>We conducted a cross-sectional online survey of US-based obstetricians, obstetrical residents, and midwives (September 2024 and July 2025). Respondents who performed IPD testing or did not provide inpatient postpartum care were excluded. Survey items assessed demographics, current testing practices, familiarity, willingness, and implementation barriers and facilitators. Analyses included chi-square, Fisher's exact tests, and <i>t</i>-tests. <i>p</i> values < 0.05 were considered significant.</p><p><strong>Results: </strong>Among the 171 respondents, most were obstetricians (87.1%), predominantly female (93%) and White (57.1%), with a mean age of 41.6 years and 13.7 years in practice across diverse US settings. Willingness to adopt IPD testing was not associated with demographics but was higher among clinicians with prior IPD experience (<i>p</i> = 0.03) and greater familiarity (<i>p</i> = 0.002). Overall, 42.7% were completely unfamiliar with IPD testing, and willingness increased with familiarity (<i>p</i> < 0.05). Key barriers included a lack of familiarity, concerns about patient fasting, perceived lack of ACOG endorsement, and the absence of protocols. Major facilitators were explicit ACOG endorsement, institutional protocols and order sets, and patient education materials.</p><p><strong>Conclusion: </strong>Obstetricians and midwives demonstrate a strong willingness to adopt IPD testing; however, implementation may be limited by knowledge gaps and system-level barriers. Education, guideline endorsement, institutional policies, and standardized protocols may improve implementation.</p>","PeriodicalId":520540,"journal":{"name":"Pregnancy (Hoboken, N.J.)","volume":"2 5","pages":"e70378"},"PeriodicalIF":0.0,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13523854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148852252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of quantitative and graduated estimated blood loss in detection of postpartum hemorrhage after spontaneous vaginal delivery.","authors":"Alesha White, R Nicholas Burns, Jessica E Pruszynski, Deepa Ravindra, Tiffany Montgomery, Kristina X Fin, Brenda Anyaehie, Elaine L Duryea","doi":"10.1002/pmf2.70385","DOIUrl":"10.1002/pmf2.70385","url":null,"abstract":"<p><strong>Objective: </strong>To compare the performance of quantitative blood loss (QBL) to graduated estimated blood loss (EBL) for prediction of clinical outcomes in spontaneous vaginal deliveries (SVDs).</p><p><strong>Methods: </strong>Prospective observational study including SVDs with a recorded QBL at a single institution. QBL was calculated and recorded in the electronic medical record by the nurse following delivery with the providers pragmatically blinded to these calculations. Providers used clinical indices and a graduated EBL, assigned prior to QBL calculation, to diagnose postpartum hemorrhage (PPH) with a specific postpartum acuity-based observation process for patients with PPH. PPH was defined as blood loss >500 cc. EBL and QBL were directly compared for the purposes of this investigation. Performance characteristics were calculated for EBL and QBL with regard to detection of transfusion and decrease in hematocrit greater than 10% (ΔHct ≥ 10) from the day of delivery to postpartum day one. Patients with discrepancies between QBL and EBL were examined with odds ratios of transfusion and ΔHct ≥ 10 calculated.</p><p><strong>Results: </strong>There were a total of 8107 SVDs. Rates of PPH were higher when defined by QBL (17% vs. 9%), with a 2.5% rate of transfusion. A discrepancy >500 cc between QBL and EBL was found in 226 (3%) patients. PPH as defined by EBL demonstrated lower sensitivity but higher specificity, PPV, and NPV for transfusion and higher specificity and PPV for ΔHct ≥ 10. When examining deliveries with EBL ≤ 500 cc but QBL ≥ 500 cc, odds of transfusion (odds ratio [OR], 1.41; 95% confidence interval [CI], 1.02-1.93) and ΔHct ≥ 10 (OR, 2.94; 95% CI, 2.39-3.59) were increased. Conversely, this was true in cases of EBL ≥ 500 cc with a QBL ≤ 500 cc, with an odds of transfusion (OR, 6.38; 95% CI, 4.43-9.01) and ΔHct ≥ 10 of 3.41 (95% CI, 2.41-4.47). For every 2700 deliveries in which QBL was used to guide care, one additional transfusion would be identified versus using EBL alone.</p><p><strong>Conclusion: </strong>Graduated EBL demonstrates higher specificity for transfusion and ΔHct ≥ 10 when compared to QBL. In an environment with a standardized graduated EBL and an acuity-based postpartum observation process, QBL does not offer additional benefits after SVD. In places with limited resources, graduated EBL is a good alternative to QBL.</p>","PeriodicalId":520540,"journal":{"name":"Pregnancy (Hoboken, N.J.)","volume":"2 5","pages":"e70385"},"PeriodicalIF":0.0,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13523855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148852224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intellectual and developmental disability diagnoses in California delivery records and adverse maternal outcomes.","authors":"Catherine Psaras, Rita H Ryu, Rebecca J Baer, Kristin Palmsten, Jerasimos Ballas, Jaime Barea, Jeanne Townsend, Timothy Wen, Talya Tasini, Gretchen Bandoli","doi":"10.1002/pmf2.70435","DOIUrl":"10.1002/pmf2.70435","url":null,"abstract":"<p><strong>Background: </strong>Women with intellectual and developmental disability (IDD) are a population whose maternal health outcomes remain poorly documented. We estimated associations between maternal IDD diagnosis in California birth records and adverse maternal outcomes, and assessed whether prenatal clinical characteristics mediate these relationships.</p><p><strong>Methods: </strong>This retrospective population-based cohort study included all deliveries ≥22 weeks' gestation in California between 2007 and 2021, using birth and fetal death certificates linked to inpatient and emergency department records. Outcomes included severe maternal morbidity (SMM), cesarean delivery, preeclampsia, and maternal hospital admission in the year following delivery. We calculated adjusted risk ratios (aRRs) matched on maternal age and year of delivery. We examined IDD as a single category and by subtype: autism spectrum disorder (ASD), cerebral palsy (CP), intellectual disability (ID), chromosomal differences, and other IDDs. Mediators included tobacco use, pre-existing hypertension, pre-existing diabetes, preeclampsia, prepregnancy body mass index, epilepsy, depression/anxiety, bipolar disorder or schizophrenia, and adequate prenatal care.</p><p><strong>Results: </strong>Among 6,435,742 singleton births, 4492 mothers (0.07%) had an IDD diagnosis. Women with IDD faced elevated risks across all adverse outcomes compared to those without: SMM-aRR: 2.77, 95% CI: 2.40, 3.19; cesarean delivery-aRR: 1.44, 95% CI: 1.39, 1.50; preeclampsia-aRR: 2.52, 95% CI: 2.30, 2.77; and hospital admission within 1 year of delivery-aRR: 4.64, 95% CI: 4.26, 5.05. While risk was elevated for all subtypes across all outcomes, ID tended to confer the highest risk. In the mediation analysis, hypertensive disorders and mental health conditions were the strongest individual mediators. In a joint mediation analysis, select perinatal characteristics explained half of the excess risk of cesarean delivery (autism), preeclampsia (autism), hospital admission (ID), and SMM (ID).</p><p><strong>Conclusions: </strong>Women with IDD documented in California birth records face substantially elevated risks of adverse maternal outcomes, with the largest disparities in hospital admission in the year following delivery. Hypertensive disorders, depression, and anxiety were the strongest potential mediators of those analyzed, and should be further evaluated as intervention targets. Given our reliance on inpatient diagnostic codes, findings may generalize most reliably to women with IDD with the highest support needs.</p>","PeriodicalId":520540,"journal":{"name":"Pregnancy (Hoboken, N.J.)","volume":"2 5","pages":"e70435"},"PeriodicalIF":0.0,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13523856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148852228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The minimum requirements for prenatal \"confirmatory\" diagnosis of fetal aneuploidy.","authors":"Jose Carlos Ferreira, Brynn Levy, Peter Benn","doi":"10.1002/pmf2.70440","DOIUrl":"10.1002/pmf2.70440","url":null,"abstract":"","PeriodicalId":520540,"journal":{"name":"Pregnancy (Hoboken, N.J.)","volume":"2 5","pages":"e70440"},"PeriodicalIF":0.0,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13522834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148852240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Society for Maternal-Fetal Medicine Special Statement: Checklist for initial management of amniotic fluid embolism-Updated 2026.","authors":"L Carolina Martinez-King, C Andrew Combs, Douglas M Montgomery, Lorraine E Toner, Gary A Dildy","doi":"10.1002/pmf2.70364","DOIUrl":"10.1002/pmf2.70364","url":null,"abstract":"<p><p>Amniotic fluid embolism is a rare syndrome characterized by sudden cardiorespiratory collapse during labor or soon after delivery. Because of its rarity, many obstetrical providers have no experience in managing amniotic fluid embolism and may therefore benefit from a cognitive aid such as a checklist. In 2021, the Society for Maternal-Fetal Medicine published a sample checklist for the initial management of amniotic fluid embolism based on standard management guidelines. In this article, we present an updated checklist with revisions to align the terminology with advanced cardiac life support guidelines. We also suggest steps that each facility can take to implement the checklist effectively. This Special Statement replaces Society for Maternal-Fetal Medicine Special Statement: Checklist for initial management of amniotic fluid embolism, 2021.</p>","PeriodicalId":520540,"journal":{"name":"Pregnancy (Hoboken, N.J.)","volume":"2 5","pages":"e70364"},"PeriodicalIF":0.0,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13565333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}